DexCom (NASDAQ:DXCM) Price Target Lowered to $80.00 at Wells Fargo & Company

DexCom (NASDAQ:DXCM) had its price objective lowered by analysts at Wells Fargo & Company from $145.00 to $80.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company‘s target price would indicate a potential downside of 25.82% from the company’s previous close.

DXCM has been the topic of a number of other research reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price objective on shares of DexCom in a report on Tuesday. Redburn Atlantic started coverage on DexCom in a report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective on the stock. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $145.00 to $75.00 in a report on Friday. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Finally, UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $130.60.

DexCom Stock Down 3.7 %

Shares of NASDAQ:DXCM opened at $107.85 on Friday. DexCom has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm’s 50-day simple moving average is $116.63 and its 200-day simple moving average is $124.29. The company has a market cap of $42.89 billion, a price-to-earnings ratio of 69.58, a PEG ratio of 2.74 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the company earned $0.34 EPS. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, equities research analysts predict that DexCom will post 1.78 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at approximately $9,773,267.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders sold 4,112 shares of company stock worth $480,861 in the last ninety days. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DXCM. Capital World Investors raised its holdings in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares during the last quarter. Norges Bank acquired a new position in DexCom in the 4th quarter valued at $540,178,000. Artisan Partners Limited Partnership raised its holdings in DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after acquiring an additional 3,672,471 shares during the last quarter. Capital Research Global Investors raised its holdings in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after acquiring an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new stake in shares of DexCom during the 4th quarter worth $231,773,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.